Director/PDMR Shareholding

Released : 24 Apr 2017 12:30

RNS Number : 1418D
Dechra Pharmaceuticals PLC
24 April 2017
 



 

 

 

24 April 2017

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company) 

 

 

In accordance with article 19(1) of the Market Abuse Regulations, the Company was notified today that due to a change in personal circumstances Ian Page's total beneficial interest in the Company is now 811,308 shares, which represents 0.871% of the current issued share capital.

 

The reduction in his beneficial shareholding relates to shares held by his sons, Andrew, David and Michael Page, who are no longer classified as a connected person under the Market Abuse Regulations.

 

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Ian Page

 

2.

Reason for the notification

a)

Position/status

Director

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

N/A

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Shares held by sons, who are no longer connected people

c)

Price(s) and volumes(s)

Price(s)

Nil cost

Nil cost

Nil cost

Volume(s)

2,600

2,000

2,000

d)

Aggregated information

-   Aggregate volume

-   Price

 

 

6,600

 

Nil cost

e)

Date of the transaction

2017.04.24

f)

Place of the transaction

Outside a trading venue

 

 

 

For further information, please contact:

 

Suzana Cross, Company Secretary           

Telephone number: 01606 814730

 

 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHOKQDBDBKDCQB